Protein tyrosine tyrosine - Novo nordiskAlternative Names: NN 9748; NN9747; PYY-1562
Latest Information Update: 20 Feb 2016
At a glance
- Originator Novo Nordisk
- Class Peptide hormones
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Obesity; Type 2 diabetes mellitus
Most Recent Events
- 17 Feb 2016 Phase-I clinical trials in Obesity in Denmark (unspecified route) prior to February 2016 (Novo Nordisk's pipeline, February 2016)
- 17 Feb 2016 Phase-I clinical trials in Type-2 diabetes mellitus in Denmark (unspecified route) prior to February 2016 (Novo Nordisk's pipeline, February 2016)